Published on : Nov 14, 2017
Albany, New York, November 14, 2017: A latest pipeline report, titled “Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 18.104.22.168) - Pipeline Review, H2 2017” has been included in the extensive research repository of Market Research Hub (MRH) recently. This report outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by companies/universities. According to this report, pipeline target mainly constitutes close to 11 molecules. Approximately 9 molecules are developed by companies and continuing by the universities/institutes.
Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. One of the most important features of this enzyme is that the protein is an adipokine which is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.
In the initial section, the report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase. Then, it acutely reviews targeted therapeutics that are ongoing by companies and universities. Analysis of pipeline products based on various stages of development is also offered to the readers. It covers products from therapy areas Oncology, Central Nervous System, Immunology and Respiratory which include indications Acute Lymphocytic Leukemia, Acute Myelocytic Leukemia, Age-Related Memory Impairment, Amyotrophic Lateral Sclerosis, Depression, Multiple Myeloma (Kahler Disease), Nerve Injury, Parkinsons Disease, Acute Lung Injury, Leukemias, Breast Cancer, Colon Cancer, Inflammation, Lung Cancer, Non-Hodgkin Lymphoma, Pain, Pancreatic Cancer, Renal Cell Carcinoma, Sarcomas and Solid Tumor.
Further, the report reflects drug profiles for the products in the pipeline that involves product description, research and development briefing, descriptive mode of administration (MoA), collaboration and licensing details as well as various development activities. The report also assesses all the discontinued as well as dormant projects during this timeline. It also includes assessment of the latest deals and news associated with Phosphoribosyltransferase targeted therapeutics. As per the report, one of the latest featured news and press releases is that Karyopharm announces presentation of kpt-9274 clinical data at European society of medical oncology 2017 annual meeting.
At last, the research report also includes profiling of key companies involved in Therapeutics Development. Their product portfolio, key financials, strategies, pricing analysis, mergers and acquisitions, etc., has been discussed in this research report. The information on these players has been collected through SEC filings, company websites, university reports, proprietary databases, investor presentations, third-party sources and several press releases. Key players include Aurigene Discovery Technologies Ltd., OncoTartis Inc., Angelini Group, Karyopharm Therapeutics Inc, AbbVie Inc and Genentech Inc.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1361343
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org